Haloperidol and clozapine affect social behaviour in rats postnatally lesioned in the ventral hippocampus

Pharmacology Biochemistry and Behavior

Volumn 76, Issue 1, 2003, Pages 1-8

  Becker, Axel ^a   Grecksch, Gisela ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Clozapine; Diazepam; Haloperidol; Rat; Schizophrenia; Social behaviour; Ventral hippocampus

Indexed keywords

CLOZAPINE; DIAZEPAM; HALOPERIDOL; IBOTENIC ACID; NEUROLEPTIC AGENT;

AGGRESSIVENESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DRUG EFFECT; HIPPOCAMPUS; MALE; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PUBERTY; RAT; SOCIAL BEHAVIOR; SOCIAL INTERACTION; STATISTICAL SIGNIFICANCE;

ANIMALS; ANIMALS, NEWBORN; CLOZAPINE; HALOPERIDOL; HIPPOCAMPUS; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; SOCIAL BEHAVIOR;

ANIMALIA;

EID: 1642344758     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(03)00139-4     Document Type: Article

References (57)

1. Abi-Dargham A., Laruelle M., Krystal J., D'Souza C., Zoghbi S., Baldwin R.M.et al. No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology. 20:1999;650-661.
2. Andreasen N.C., Carpenter W.T.J. Diagnosis and classification of schizophrenia. Schizophr. Bull. 19:1993;199-214.
3. Arnold S.E. Neurodevelopmental abnormalities in schizophrenia: insights from neuropathology. Dev. Psychopathol. 11:1999;439-456.
4. Ashton H. Brain function and psychotropic drugs. 1992;Oxford Univ. Press, Oxford.
5. Baldessarini R., Centorrino F., Flood J., Volpicelli S., Huston-Lyon D., Cohen B. Tissue concentrations of clozapine and ist metabolites in the rat. Psychopharmacology. 9:1993;117-124.
6. Becker A., Grecksch G., Bernstein H.G., Höllt V., Bogerts B. Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology. 144:1999;333-338.
7. Bogerts B. Recent advances in the neuropathology of schizophrenia. Schizophr. Bull. 19:1993;431-445.
8. Bogerts B. The temporolimbic system theory of positive schizophrenic symptoms. Schizophr. Bull. 23:1997;423-435.
9. Brar J.S., Chengappa K.N., Parepally H., Sandman A.R., Kreinbrook S.B., Sheth S.A.et al. The effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms. Ann. Clin. Psychiatry. 9:1997;227-234.
10. Breier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., Summerfelt A.et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry. 151:1994;20-26.
11. Bruhwyler J., Chleide E., Liegeois J.F., Delarge J., Mercier M. Anxiolytic potential of sulpiride, clozapine and derivatives in the open-field test. Pharmacol. Biochem. Behav. 36:1990;57-61.
12. Cannon M., Murray R.M. Neonatal origins of schizophrenia. Arch. Disease Child. 78:2000;1-3.
13. Canon J.G. A comparison of clozapine, chlorpromazine and thioridazine upon DRL performance in the squirrel monkey. Psychopharmacology. 64:1979;55-60.
14. Canon J.G., Lippa A.S. Use of DRL in differentiating anxiolytic and neuroleptic properties of CNS drugs. Pharmacol. Biochem. Behav. 6:1977;591-593.
15. Carpenter W.R.J., Buchanan R.W., Kirkpatrick B., Breier A.F. Diazepam treatment of early signs of exacerbation in schizophrenia. Am. J. Psychiatry. 156:1999;299-303.
16. Cheng Y., Paalzow L. Linear pharmacokinetics of haloperidol in the rat. Biopharm. Drug Dispos. 13:1992;69-76.
17. Compton A.D., Slemmer J.E., Drew M.R., Hyman J.M., Golden K.M., Balster R.L.et al. Combinations of clozapine and phencyclidine: effects on drug discrimination and behavioural inhibition in rats. Neuropharmacology. 40:2001;289-297.
18. Corbett R., Hartman H., Kerman L.L., Woods A.T., Strupczewski J.T., Helsley G.C.et al. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol. Biochem. Behav. 45:1993;9-17.
19. Duncan G.E., Sheitman B.B., Lieberman J.A. An integrated view of pathophysiological models of schizophrenia. Brain Res. Brain Res. Rev. 29:1999;250-264.
20. Fernandes C., File S.E. Dizocilpine does not prevent the development of tolerance to the anxiolytic effects of diazepam in rats. Brain Res. 815:1999;431-434.
21. File SE. The social interaction test of anxiety. Neuroscience Protocols 93-010-01-07; 1993.
22. Gobbi G., Janiri L. Clozapine blocks dopamine, 5-HT2 and 5-HT3 responses in the medial prefrontal cortex: an in vivo microiontophoretic study. Eur. Neuropsychopharmacol. 10:1999;43-49.
23. Graeff F.G., Netto C.F., Zangrossi H.J. The elevated T-maze as an experimental model of anxiety. Neurosci. Biobehav. Rev. 23:1998;237-246.
24. Grecksch G., Bernstein H.G., Becker A., Höllt V., Bogerts B. Disruption of latent inhibition in rats with postnatal hippocampal lesions. Neuropsychopharmacology. 20:1999;525-532.
25. Harrison P.J. Schizophrenia: a disorder of neurodevelopment? Curr. Opin. Neurobiol. 7:1997;285-289.
26. Hartman D., Monsma F., Civelli O. Interaction of antipsychotic drugs with dopamine receptor subtypes. Csernansky J.G. Handbook of experimental pharmacology. 1996;43-75 Springer, Berlin.
27. Heyman I., Murray R.M. Schizophrenia and neurodevelopment. J. R. Coll. Physicians Lond. 26:1992;143-146.
28. 4 receptors in rat frontal cortex. J. Neural Transm. Gen. Sect. 101:1995;231-235.
29. Lieberman J.A. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry. 46:1999;729-739.
30. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology. 17:1997;205-229.
31. Lingjaerde O. Benzodiazepines in the treatment of schizophrenia: an updated survey. Acta Psychiatr. Scand. 84:1991;453-459.
32. Lipska B.K., Weinberger D.R. Cortical regulation of the mesolimbic dopamine system: implications for schizophrenia. Kalivas P., Barnes C. 1993;329-349 CRC Press, Boca Raton.
33. Lipska B.K., Swerdlow N.R., Geyer M.A., Jaskiw G.E., Braff D.L., Weinberger D.R. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology. 122:1995;35-43.
34. McDonald L.M., Morgan P.M., Vythelingum G.N., Joseph M.H., Stephenson J.D., Gray J.A. Enhancement of latent inhibition by two 5-HT2a receptor antagonists only when given at both pre-exposure and conditioning. Psychopharmacology. 2002;. [DOI 10.1007/s00213-002-1173-4. Published online 9 August 2002].
35. Meltzer H.Y. Clinical studies on the mechanisms of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology. 99:1989;S18-S27. [Supplement].
36. Meltzer H.Y. The mechanisms of action of novel antipsychotic drugs. Schizophr. Bull. 17:1991;263-287.
37. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 21:1999;106S-115S.
38. Menard J., Treit D. Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci. Biobehav. Rev. 23:1999;591-613.
39. Miller D.D., Perry P.J., Cadoret R.J., Andreasen N.C. Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr. Psychiatry. 35:1994;8-15.
40. Nakazato A., Okuyama S. Recent advances in novel atypical antipsychotic agents: potential therapeutic agents for the treatment of schizophrenia. Exp. Opin. Ther. Pat. 10:2000;75-96.
41. O'Donnell P., Grace A.A. Basic neurophysiology of antipsychotic drug action. Csernansky J.G. Handbook of experimental pharmacology. 1996;163-202 Springer, Berlin.
42. Öhman R., Larsson M., Nilsson I.M., Engel J., Carlsson A. Neurometabolic and behavioural effects of haloperidol in relation to drug levels in serum and brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 299:1977;105-114.
43. Paxinos G., Watson G. The rat brain in stereotaxic coordinates. 1997;Academic Press, San Diego.
44. Pilowsky L.S., Kerwin R.W., Murray R.M. Schizophrenia: a neurodevelopmental perspective. Neuropsychopharmacology. 9:1993;83-91.
45. Qiao H., Noda Y., Kamei H., Nagai T., Furukawa H., Miura H.et al. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. NeuroReport. 12:2001;11-15.
46. Rex A., Voigt J.P., Voits M., Fink H. Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs. Pharmacol. Biochem. Behav. 59:1998;677-683.
47. Sams-Dodd F. Effect of novel antipsychotic drugs on phencyclidine- induced stereotyped behaviour and social isolation in the rat social interaction test. Behav. Pharmacol. 8:1997;196-215.
48. Sams-Dodd F. Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Neurosci. Biobehav. Rev. 23:1998;287-293.
49. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev. Neurosci. 10:1999;59-90.
50. Sams-Dodd F., Lipska B.K., Weinberg D.R. Neonatal lesion of the ventral hippocampus results in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology. 104:1991;303-310.
51. Schmidt C.J., Sorensen S.M., Kehne J.H., Carr A.A., Palfreyman M.G. The role of 5-HT2A receptors in antipsychotic activity. Life Sci. 56:1995;2209-2222.
52. 4 receptors by 2-fold in rats. Eur. J. Pharmacol. 289:1995;67-72.
53. 4-like dopamine receptors. Neuropsychopharmacology. 17:1997;186-196.
54. Van Kammen D.P., Guidotti A., Kelley M.E., Gurklis J., Guarneri P., Gilbertson M.W.et al. CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships. Biol. Psychiatry. 34:1993;515-522.
55. Weinberger D.R. From neuropathology to neurodevelopment. Lancet. 346:1995;552-557.
56. Wongwitdecha N., Marsden C.A. Social isolation increases aggressive behaviour and alters the effects of diazepam in the rat social interaction test. Behav. Brain Res. 75:1996;27-32.
57. Worrel J.A., Marken P.A., Beckman S.E., Ruehter V.L. Atypical antipsychotic agents: a critical review. Am. J. Health-Syst. Pharm. 57:2000;238-255.